EHA 2022 | Managing ALL patients who relapse after transplantation

Name: Managing ALL patients who relapse after transplantation
Uploaded: 2022-06-12T00:00:00Z
Duration: 1 min 14 s
Description: Sabina Chiaretti, MD, PhD, Sapienza University of Rome, Rome, Italy, shares some insights into the management of patients with acute lymphoblastic leukemia (ALL) who relapse after transplantation, including the promise of monoclonal antibodies and CAR-T therapy. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Sabina Chiaretti • 12 Jun 2022

EHA 2022

Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab CAR-T Inotuzumab ozogamicin

Sabina Chiaretti, MD, PhD, Sapienza University of Rome, Rome, Italy, shares some insights into the management of patients with acute lymphoblastic leukemia (ALL) who relapse after transplantation, including the promise of monoclonal antibodies and CAR-T therapy. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.